Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.
Clinical trial NCT07603791 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07603791
- Sponsor
- Shanghai Allink Biotherapeutics Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-06-30
- Primary completion
- 2027-12-30
- Enrollment
- 252
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.